SCHEMBL219530

SCHEMBL219530

Oc1cccc(C2CCCCC2)c1

nearest known ligand 0.66

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.59
HDAC2 Q92769 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
KMO O15229 1/20 0.58
DRD2 P14416 3/20 0.54
SIGMAR1 Q99720 3/20 0.54
DRD4 P21917 2/20 0.54
DRD3 P35462 2/20 0.54
NFKB1 P19838 1/20 0.54
PRCP P42785 1/20 0.54
EBP Q15125 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4959143 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL3356779 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL4962000 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL4961955 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL5272910 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL31123519 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL1982025 1.00 HDAC4 (0.59) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL28703324 0.98 HDAC4 (0.58) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL1661863 0.98 HDAC4 (0.61) HDAC4HDAC2HDAC8KMODRD2
SCHEMBL1658753 0.94 HDAC4 (0.56) HDAC4HDAC2HDAC8DRD2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114276530-B Intermittent phosgene interface method preparation process and application of polycarbonate 广州市德力塑化工科技有限公司 2023-04-21 CN claimed
CN-114276530-A Intermittent phosgene interface method preparation process of polycarbonate and application thereof 深圳市德力塑化工科技有限公司 2022-04-05 CN claimed
EP-3215269-B1 PROCESS FOR PRODUCING ORTHOPHENYLPHENOL (OPP) LANXESS DEUTSCHLAND GMBH (DE) 2020-05-13 EP claimed
EP-3053992-A1 Biodiesel LANXESS Deutschland GmbH (DE) 2016-08-10 EP claimed
EP-2684900-B1 RADICALLY CURABLE COMPOUND, CURED PRODUCT OF SAME, AND METHOD FOR PRODUCING SAME DAINIPPON INK & CHEMICALS (JP) 2016-03-02 EP claimed
US-8816033-B2 Radically curable compound, cured product thereof, and method for producing the compound DIC CORPORATION (JP) 2014-08-26 US claimed
US-20130338329-A1 RADICALLY CURABLE COMPOUND, CURED PRODUCT THEREOF, AND METHOD FOR PRODUCING THE COMPOUND DIC CORPORATION (JP) 2013-12-19 US claimed
US-5322919-A Transesterification in an inert solvent IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1994-06-21 US claimed
US-3932536-A DEHYDROGENATION CATALYST, NI, CR, AL, CU, 1A SULFATE OR CARBONATE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-13 US claimed
JP-4193863-A None JP disclosed
US-20260001987-A1 POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF MITSUBISHI CHEMICAL CORPORATION (JP) 2026-01-01 US disclosed
US-12486239-B2 Benzotriazole compound, light absorber, and resin composition MITSUI CHEMICALS, INC. (JP) 2025-12-02 US disclosed
US-12460048-B2 Thermoplastic resin composition and formed product MITSUBISHI CHEMICAL CORPORATION (JP) 2025-11-04 US disclosed
EP-4023698-B1 THERMOPLASTIC RESIN COMPOSITION AND FORMED PRODUCT MITSUBISHI CHEM CORP (JP) 2025-10-22 EP disclosed
US-4075220-A FOR POLYMERS EASTMAN KODAK COMPANY (US) 1978-02-21 US disclosed
US-4013708-A ANTIALLERGENS CIBA-GEIGY CORPORATION (US) 1977-03-22 US disclosed
US-4013690-A ORGANIC COMPOUNDS SANDOZ LTD. (CH) 1977-03-22 US disclosed
US-3957813-A BENZOXAZOLYL PHENYL AROMATIC ESTER COMPOUNDS AND THEIR USE AS ULTRAVIOLET STABILIZERS IN ORGANIC COMPOSITIONS EASTMAN KODAK COMPANY (US) 1976-05-18 US disclosed
US-3933924-A Process for preparing hydroxydiphenyl BAYER AKTIENGESELLSCHAFT (DT) 1976-01-20 US disclosed
US-3932536-A DEHYDROGENATION CATALYST, NI, CR, AL, CU, 1A SULFATE OR CARBONATE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338329-A1 RADICALLY CURABLE COMPOUND, CURED PRODUCT THEREOF, AND METHOD FOR PRODUCING THE COMPOUND CBR1, HEATR1, MTR HDAC4 827/4885HDAC2 1144/4885HDAC8 1476/4885
US-20260001987-A1 POLYCARBONATE RESIN COMPOSITION AND MOLDED ARTICLE THEREOF SEM1, WDR1, TAF1 HDAC4 1002/4885HDAC2 803/4885HDAC8 652/4885
US-12486239-B2 Benzotriazole compound, light absorber, and resin composition SULT1A1, BET1, SULT1E1 HDAC4 462/4885HDAC2 330/4885HDAC8 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.